Fabienne Rajas

List of Publications by Year
in descending order

75 papers	3,729 citations	147801 31 h-index	133252 59 g-index
85 all docs	85 docs citations	85 times ranked	5029 citing authors

#	Article	IF	Citations
1	Cellular and metabolic effects of renin-angiotensin system blockade on glycogen storage disease type I nephropathy. Human Molecular Genetics, 2022, 31, 914-928.	2.9	4
2	Increased atherosclerosis in a mouse model of glycogen storage disease type 1a. Molecular Genetics and Metabolism Reports, 2022, 31, 100872.	1.1	1
3	A hypometabolic defense strategy against malaria. Cell Metabolism, 2022, 34, 1183-1200.e12.	16.2	10
4	Intestinal gluconeogenesis and protein diet: future directions. Proceedings of the Nutrition Society, 2021, 80, 118-125.	1.0	4
5	The absence of hepatic glucose-6 phosphatase/ChREBP couple is incompatible with survival in mice. Molecular Metabolism, 2021, 43, 101108.	6.5	14
6	Impaired <scp>Veryâ€Lowâ€Density Lipoprotein</scp> catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease typeÂIa. Journal of Inherited Metabolic Disease, 2021, 44, 879-892.	3.6	13
7	mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease. Nature Communications, 2021, 12, 3090.	12.8	35
8	Tamoxifen Treatment in the Neonatal Period Affects Glucose Homeostasis in Adult Mice in a Sex-Dependent Manner. Endocrinology, 2021, 162, .	2.8	8
9	Hepatocyte-specific glucose-6-phosphatase deficiency disturbs platelet aggregation and decreases blood monocytes upon fasting-induced hypoglycemia. Molecular Metabolism, 2021, 53, 101265.	6.5	3
10	Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels. Human Molecular Genetics, 2020, 29, 264-273.	2.9	13
11	Intestinal gluconeogenesis prevents obesity-linked liver steatosis and non-alcoholic fatty liver disease. Gut, 2020, 69, 2193-2202.	12.1	37
12	Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a. Hepatology, 2020, 72, 1638-1653.	7.3	34
13	Challenges of Gene Therapy for the Treatment of Glycogen Storage Diseases Type I and Type III. Human Gene Therapy, 2019, 30, 1263-1273.	2.7	16
14	Master role of glucose-6-phosphate in cell signaling and consequences of its deregulation in the liver and kidneys. , 2019, , 173-189.		1
15	Glucoseâ€6â€Phosphate Regulates Hepatic Bile Acid Synthesis in Mice. Hepatology, 2019, 70, 2171-2184.	7.3	21
16	Glucose-6 Phosphate, a Central Hub for Liver Carbohydrate Metabolism. Metabolites, 2019, 9, 282.	2.9	52
17	Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease. Molecular Therapy - Methods and Clinical Development, 2019, 15, 383-391.	4.1	10
18	Hepatic stress associated with pathologies characterized by disturbed glucose production. Cell Stress, 2019, 3, 86-99.	3.2	20

#	Article	IF	Citations
19	Adaptation of Hepatic, Renal, and Intestinal Gluconeogenesis During Food Deprivation. , 2019, , 2133-2147.		0
20	G6PC mRNA Therapy Positively Regulates Fasting Blood Glucose and Decreases Liver Abnormalities in a Mouse Model of Glycogen Storage Disease 1a. Molecular Therapy, 2018, 26, 814-821.	8.2	51
21	Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia. Journal of Hepatology, 2018, 69, 1074-1087.	3.7	31
22	Inhibition of Glycogen Synthase II with RNAi Prevents Liver Injury in Mouse Models of Glycogen Storage Diseases. Molecular Therapy, 2018, 26, 1771-1782.	8.2	24
23	The role of kidney in the inter-organ coordination of endogenous glucose production during fasting. Molecular Metabolism, 2018, 16, 203-212.	6.5	15
24	Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context. Molecular Metabolism, 2018, 16, 100-115.	6.5	46
25	Polycystic kidney features of the renal pathology in glycogen storage disease type I: possible evolution to renal neoplasia. Journal of Inherited Metabolic Disease, 2018, 41, 955-963.	3.6	13
26	Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control. Journal of Inherited Metabolic Disease, 2017, 40, 695-702.	3.6	19
27	Metabolic Adaptation Establishes Disease Tolerance to Sepsis. Cell, 2017, 169, 1263-1275.e14.	28.9	207
28	Gut-Brain Glucose Signaling in Energy Homeostasis. Cell Metabolism, 2017, 25, 1231-1242.	16.2	128
29	Hepatocytes contribute to residual glucose production in a mouse model for glycogen storage disease type Ia. Hepatology, 2017, 66, 2042-2054.	7.3	18
30	Adaptation of Hepatic, Renal and Intestinal Gluconeogenesis During Food Deprivation. , 2017, , 1-15.		0
31	Mechanisms by Which Metabolic Reprogramming in GSD1 Liver Generates a Favorable Tumorigenic Environment. FIRE Forum for International Research in Education, 2016, 4, 232640981667942.	0.7	11
32	Liver PPARÎ± is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut, 2016, 65, 1202-1214.	12.1	494
33	The suppression of hepatic glucose production improves metabolism and insulin sensitivity in subcutaneous adipose tissue in mice. Diabetologia, 2016, 59, 2645-2653.	6.3	8
34	Progressive development of renal cysts in glycogen storage disease type I. Human Molecular Genetics, 2016, 25, 3784-3797.	2.9	20
35	Hepatic lentiviral gene transfer prevents the long-term onset of hepatic tumours of glycogen storage disease type 1a in mice. Human Molecular Genetics, 2015, 24, 2287-2296.	2.9	19
36	Lessons from new mouse models of glycogen storage disease type 1a in relation to the time course and organ specificity of the disease. Journal of Inherited Metabolic Disease, 2015, 38, 521-527.	3.6	18

#	Article	IF	Citations
37	Review of the nutritional benefits and risks related to intense sweeteners. Archives of Public Health, 2015, 73, 41.	2.4	31
38	Targeted deletion of kidney glucose-6 phosphatase leads to nephropathy. Kidney International, 2014, 86, 747-756.	5.2	45
39	A link between hepatic glucose production and peripheral energy metabolism via hepatokines. Molecular Metabolism, 2014, 3, 531-543.	6.5	49
40	Intestinal gluconeogenesis is crucial to maintain a physiological fasting glycemia in the absence of hepatic glucose production in mice. Metabolism: Clinical and Experimental, 2014, 63, 104-111.	3.4	48
41	A liver Hif-2Î±â€"Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition. Nature Medicine, 2013, 19, 1331-1337.	30.7	90
42	Glycogen storage disease typeÂ1 and diabetes: Learning by comparing and contrasting the two disorders. Diabetes and Metabolism, 2013, 39, 377-387.	2.9	45
43	In vivo hepatic lipid quantification using MRS at 7 Tesla in a mouse model of glycogen storage disease type 1a. Journal of Lipid Research, 2013, 54, 2010-2022.	4.2	14
44	Mu-Opioid Receptors and Dietary Protein Stimulate a Gut-Brain Neural Circuitry Limiting Food Intake. Cell, 2012, 150, 377-388.	28.9	99
45	Glucotoxicity Induces Glucose-6-Phosphatase Catalytic Unit Expression by Acting on the Interaction of HIF-1Î± With CREB-Binding Protein. Diabetes, 2012, 61, 2451-2460.	0.6	29
46	Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas. Journal of Hepatology, 2011, 54, 529-537.	3.7	119
47	Protein-induced satiety is abolished in the absence of intestinal gluconeogenesis. Physiology and Behavior, 2011, 105, 89-93.	2.1	57
48	Control of Blood Glucose in the Absence of Hepatic Glucose Production During Prolonged Fasting in Mice. Diabetes, 2011, 60, 3121-3131.	0.6	136
49	Metabolic and melanocortin gene expression alterations in male offspring of obese mice. Molecular and Cellular Endocrinology, 2010, 319, 99-108.	3.2	16
50	Leptin Infusion and Obesity in Mouse Cause Alterations in the Hypothalamic Melanocortin System. Obesity, 2008, 16, 1763-1769.	3.0	24
51	Immunocytochemical localization of glucose 6-phosphatase and cytosolic phosphoenolpyruvate carboxykinase in gluconeogenic tissues reveals unsuspected metabolic zonation. Histochemistry and Cell Biology, 2007, 127, 555-565.	1.7	33
52	Transcriptional Regulation of the Glucose-6-phosphatase Gene by cAMP/Vasoactive Intestinal Peptide in the Intestine. Journal of Biological Chemistry, 2006, 281, 31268-31278.	3.4	46
53	Contribution of intestine and kidney to glucose fluxes in different nutritional states in rat. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2006, 143, 195-200.	1.6	53
54	Glucose utilization is suppressed in the gut of insulin-resistant high fat-fed rats and is restored by metformin. Biochemical Pharmacology, 2006, 72, 198-203.	4.4	16

#	Article	IF	Citations
55	Transcriptional Regulation of the Glucose-6-phosphatase Gene by cAMP/Vasoactive Intestinal Peptide in the Intestine. Journal of Biological Chemistry, 2006, 281, 31268-31278.	3.4	13
56	A Distal Region Involving Hepatocyte Nuclear Factor 4Î± and CAAT/Enhancer Binding Protein Markedly Potentiates the Protein Kinase A Stimulation of the Glucose-6-Phosphatase Promoter. Molecular Endocrinology, 2005, 19, 163-174.	3.7	31
57	Portal sensing of intestinal gluconeogenesis is a mechanistic link in the diminution of food intake induced by diet protein. Cell Metabolism, 2005, 2, 321-329.	16.2	168
58	Induction of control genes in intestinal gluconeogenesis is sequential during fasting and maximal in diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2004, 286, E370-E375.	3.5	101
59	A Novel Role for Glucose 6-Phosphatase in the Small Intestine in the Control of Glucose Homeostasis. Journal of Biological Chemistry, 2004, 279, 44231-44234.	3.4	103
60	Differential regulation of the glucose-6-phosphatase TATA box by intestine-specific homeodomain proteins CDX1 and CDX2. Nucleic Acids Research, 2003, 31, 5238-5246.	14.5	34
61	Polyunsaturated Fatty Acyl Coenzyme A Suppress the Glucose-6-phosphatase Promoter Activity by Modulating the DNA Binding of Hepatocyte Nuclear Factor 4Î±. Journal of Biological Chemistry, 2002, 277, 15736-15744.	3.4	79
62	Rat Small Intestine Is an Insulin-Sensitive Gluconeogenic Organ. Diabetes, 2001, 50, 740-746.	0.6	167
63	beta-Cell function and viability in the spontaneously diabetic GK rat: information from the GK/Par colony. Diabetes, 2001, 50, S89-S93.	0.6	85
64	Induction of PEPCK gene expression in insulinopenia in rat small intestine.. Diabetes, 2000, 49, 1165-1168.	0.6	90
65	Phosphatidylinositol 3-Kinase Translocates onto Liver Endoplasmic Reticulum and May Account for the Inhibition of Glucose-6-phosphatase during Refeeding. Journal of Biological Chemistry, 1999, 274, 3597-3601.	3.4	43
66	Enzymatic characterization of four new mutations in the glucose-6 phosphatase (G6PC) gene which cause glycogen storage disease type 1a. Annals of Human Genetics, 1999, 63, 141-146.	0.8	27
67	The glucose-6 phosphatase gene is expressed in human and rat small intestine: Regulation of expression in fasted and diabetic rats. Gastroenterology, 1999, 117, 132-139.	1.3	158
68	Differential Actions of the Dopamine Agonist Bromocriptine on Growth of SMtTW Tumors Exhibiting a Prolactin and/or a Somatotroph Cell Phenotype: Relation to Dopamine D2 Receptor Expression. Endocrinology, 1999, 140, 13-21.	2.8	6
69	Nuclear factor 1 regulates the distal silencer of the human PIT1/GHF1 gene. Biochemical Journal, 1998, 333, 77-84.	3.7	18
70	AP-1 and Oct-1 Transcription Factors Down-regulate the Expression of the Human PIT1/GHF1 Gene. Journal of Biological Chemistry, 1996, 271, 32349-32358.	3.4	61
71	Involvement of a Membrane-bound Form of Glutamate Dehydrogenase in the Association of Lysosomes to Microtubules. Journal of Biological Chemistry, 1996, 271, 29882-29890.	3.4	29
72	Antibody-dependent cell-mediated cytotoxicity in autoimmune thyroid disease: relationship to antithyroperoxidase antibodies. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2595-2600.	3.6	56

#	Article	IF	Citations
73	Modifications of glial metabolism of glutamate after serotonergic neuron degeneration in the hippocampus of the rat. Molecular Brain Research, 1994, 26, 1-8.	2.3	19
74	Thyroglobulin molecules internalized by thyrocytes are sorted in early endosomes and partially recycled back to the follicular lumen. Endocrinology, 1993, 132, 2645-2653.	2.8	12
75	Thyroglobulin Internalized by Thyrocytes Passes through Early and Late Endosomes. Endocrinology, 1991, 129, 2202-2211.	2.8	33